CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Dolutegravir 50 mg +2 moredrug
Likely dose
Dolutegravir 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02384395
NCT02384395N/ACompleted
CompareCT.gov

IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect

University of North Carolina, Chapel Hill·interventional·Posted Mar 10, 2015·Updated Nov 22, 2021

In Brief

A clinical study evaluating Dolutegravir 50 mg, Lamivudine 300 mg, and 1 other intervention for HIV and Acute HIV Infection. Completed, enrolled 40 participants across 2 sites.

Detailed Summary

This is a multicenter, single arm, 96-week open-label study of the safety and virologic efficacy of fixed dose combination Dolutegravir/Lamivudine/Abacavir (DTG/3TC/ABC FDC) initiated during acute HIV infection (AHI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, Acute HIV Infection
CountriesUnited States
CollaboratorsViiV Healthcare

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 10, 2015
Enrollment StartSep 1, 2015
Primary CompletionMar 6, 2020
Study CompletionSep 17, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 11.3 years ago

Interventions

Dolutegravir 50 mgdrug

Initial therapy for AHI

Lamivudine 300 mgdrug

Initial therapy for AHI

Abacavir 600 mgdrug

Initial therapy for AHI